Cancer test platform gains MTPConnect funding

A new Garvan-led project that aims to improve cancer clinical trials is one of 20 initiatives set to receive funding from MTPConnect, one of the federal government's six industry growth centres.
27 October 2017

This article was written by Yolanda Redrup and originally appeared in the Australian Financial Review on 26 October, 2017.

A new project which aims to improve cancer clinical trials by renowned research body The Garvan Institute is one of 20 initiatives set to receive more than $22.5 million in funding from MTPConnect and industry partners.

The Garvan Institute project will provide access to its genetic profiling platform to enable a clinically accredited tumour genomic test, an analysis platform, and patient-matching capabilities to optimise recruitment and treatment in cancer clinical trials.

Other initiatives to receive backing ranged from programs to boost the clinical trial skills of university graduates to creating a hub to help medtech companies build health solutions, which offers real-life testing for new products and services.

MTPConnect, one of the federal government's six industry growth centres, provided $7.4 million of the funding across the 20 projects, while 200 industry consortium partners made up the remaining $15.2 million.

To read the remainder of the article, please access it on the Australian Financial Review website.